Related references
Note: Only part of the references are listed.Does enfuvirtide increase the risk of bacterial pneumonia in patients receiving combination antiretroviral therapy?
I. Kousignian et al.
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY (2010)
Immunological success is predicted by enfuvirtide but not interleukin-2 therapy in immunodepressed patients
Jean-Paul Viard et al.
AIDS (2009)
Switch from Enfuvirtide to Raltegravir in Virologically Suppressed Multidrug-Resistant HIV-1-Infected Patients: A Randomized Open-Label Trial
Nathalie De Castro et al.
CLINICAL INFECTIOUS DISEASES (2009)
Discontinuation of Enfuvirtide in Heavily Pretreated HIV-Infected Individuals
Luigia Elzi et al.
HIV CLINICAL TRIALS (2009)
Virologic Outcomes of Changing Enfuvirtide to Raltegravir in HIV-1 Patients Well Controlled on an Enfuvirtide Based Regimen: 24-Week Results of the CHEER Study
William Towner et al.
JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES (2009)
HR-2 Mutations in Human Immunodeficiency Virus Type 1 gp41 Restore Fusion Kinetics Delayed by HR-1 Mutations That Cause Clinical Resistance to Enfuvirtide
Neelanjana Ray et al.
JOURNAL OF VIROLOGY (2009)
Enfuvirtide: A Safe and Effective Antiretroviral Agent for Human Immunodeficiency Virus-Infected Patients Shortly After Liver Transplantation
Elina Teicher et al.
LIVER TRANSPLANTATION (2009)
Outcomes of multidrug-resistant patients switched from enfuvirtide to raltegravir within a virologically suppressive regimen
Marianne Harris et al.
AIDS (2008)
Enfuvirtide does not require dose adjustment in patients with chronic kidney failure - Results of a pharmacokinetic study of enfuvirtide in HIV-1-infected patients with impaired kidney function
Pablo Tebas et al.
JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES (2008)
A randomized, controlled study evaluating an induction treatment strategy in which enfuvirtide was added to an oral, highly active antiretroviral therapy regimen in treatment-experienced patients: the INTENSE study
Bonaventura Clotet et al.
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY (2008)
Association between specific enfuvirtide resistance mutations and CD4 cell response during enfuvirtide-based therapy
Thomas E. Melby et al.
AIDS (2007)
A large prospective study assessing injection site reactions, quality of life and preference in patients using the Biojector® vs standard needles for enfuvirtide administration
M. R. Loutfy et al.
HIV MEDICINE (2007)
Combined tipranavir and enfuvirtide use associated with higher plasma tipranavir concentrations but not with increased hepatotoxicity: sub-analysis from RESIST
Francois Raffi et al.
AIDS (2007)
TORO:: Ninety-six-week virologic and immunologic response and safety evaluation of enfuvirtide with an optimized background of antiretrovirals
Jacques Reynes et al.
AIDS PATIENT CARE AND STDS (2007)
Efficacy and safety of darunavir-ritonavir at week 48 in treatment-experienced patients with HIV-1 infection in POWER 1 and 2:: a pooled subgroup analysis of data from two randomised trials
Bonaventura Clotet et al.
LANCET (2007)
Susceptibility of HIV-1 non-B subtypes and recombinant variants to Enfuvirtide
Africa Holguin et al.
JOURNAL OF CLINICAL VIROLOGY (2007)
Interruption of enfuvirtide in HIV-1-Infected adults with incomplete viral suppression on an enfuvirtide-based regimen
Steven G. Deeks et al.
JOURNAL OF INFECTIOUS DISEASES (2007)
Role of the envelope genetic context in the development of enfuvirtide resistance in human immunodeficiency virus type 1-infected patients
Beatrice Labrosse et al.
JOURNAL OF VIROLOGY (2006)
Durable efficacy of tipranavir-ritonavir in combination with an optimised background regimen of antiretroviral drugs for treatment-experienced HIV-1-infected patients at 48 weeks in the Randomized Evaluation of Strategic Intervention in multi-drug resistant patients with Tipranavir (RESIST) studies: an analysis of combined data from two randomised open-label trials
Charles B. Hicks et al.
LANCET (2006)
Genotypic changes in human immunodeficiency virus type 1 envelope glycoproteins on treatment with the fusion inhibitor enfuvirtide and their influence on changes in drug susceptibility in vitro
C. Su et al.
JOURNAL OF CLINICAL VIROLOGY (2006)
Characterization of envelope glycoprotein gp41 genotype and phenotypic susceptibility to enfuvirtide at baseline and on treatment in the phase III clinical trials TORO-1 and TORO-2
T. Melby et al.
AIDS RESEARCH AND HUMAN RETROVIRUSES (2006)
Enfuvirtide plasma levels and injection site reactions using a needle-free gas-powered injection system (Biojector)
M Harris et al.
AIDS (2006)
Safety of enfuvirtide in combination with an optimized background of antiretrovirals in treatment-experienced HIV-1-infected adults over 48 weeks
B Trottier et al.
JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES (2005)
Dynamics of enfuvirtide resistance in HIV-infected patients during and after long-term enfuvirtide salvage therapy
E Poveda et al.
JOURNAL OF CLINICAL VIROLOGY (2005)
Durable efficacy of enfuvirtide over 48 weeks in heavily treatment-experienced HIV-1-infected patients in the T-20 Versus Optimized Background Regimen Only 1 and 2 clinical trials
M Nelson et al.
JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES (2005)
Prognostic staging of extensively pretreated patients with advanced HIV-1 disease
J Montaner et al.
HIV CLINICAL TRIALS (2005)
Emergence and evolution of enfuvirtide resistance following long-term therapy involves heptad repeat 2 mutations within gp41
L Xu et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2005)
Relative replicative fitness of human immunodeficiency virus type 1 mutants resistant to enfuvirtide (T-20)
J Lu et al.
JOURNAL OF VIROLOGY (2004)
Sensitivity of HIV type 1 subtype C isolates to the entry inhibitor T-20
T Cilliers et al.
AIDS RESEARCH AND HUMAN RETROVIRUSES (2004)
Cutaneous injection site reactions to long-term therapy with enfuvirtide
P Maggi et al.
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY (2004)
Health-related quality of life with enfuvirtide (ENF; T-20) in combination with an optimized background regimen
CJ Cohen et al.
JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES (2004)
Resistance to enfuvirtide, the first HIV fusion inhibitor
ML Greenberg et al.
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY (2004)
Injection site reactions with the HIV-1 fusion inhibitor enfuvirtide
RA Ball et al.
JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY (2003)
Uncommon mutations at residue positions critical for enfuvirtide (T-20) resistance in enfuvirtide-naive patients infected with subtype B and non-B HIV-1 strains
F Roman et al.
JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES (2003)
Novel therapies based on mechanisms of HIV-1 cell entry
JM Kilby et al.
NEW ENGLAND JOURNAL OF MEDICINE (2003)
Enfuvirtide, an HIV-1 fusion inhibitor, for drug-resistant HIV infection in North and South America
JP Lalezari et al.
NEW ENGLAND JOURNAL OF MEDICINE (2003)
Efficacy of enfuvirtide in patients infected with drug-resistant HIV-1 in Europe and Australia
A Lazzarin et al.
NEW ENGLAND JOURNAL OF MEDICINE (2003)
Primary resistance mutations to fusion inhibitors and polymorphisms in gp4l sequences of HIV-1 non-B subtypes and recombinants
ML Villahermosa et al.
AIDS (2003)
A phase II clinical study of the long-term safety and antiviral activity of enfuvirtide-based antiretroviral therapy
JP Lalezari et al.
AIDS (2003)
Entry inhibitors SCH-C, RANTES, and T-20 block HIV type 1 replication in multiple cell types
TJ Ketas et al.
AIDS RESEARCH AND HUMAN RETROVIRUSES (2003)
HIV-1 cell entry and advances in viral entry inhibitor therapy
LA Cooley et al.
JOURNAL OF CLINICAL VIROLOGY (2003)
Sensitivity of HIV-1 to entry inhibitors correlates with envelope/coreceptor affinity, receptor density, and fusion kinetics
JD Reeves et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2002)
The safety, plasma pharmacokinetics, and antiviral activity of subcutaneous enfuvirtide (T-20), a peptide inhibitor of gp41-mediated virus fusion, in HIV-infected adults
JM Kilby et al.
AIDS RESEARCH AND HUMAN RETROVIRUSES (2002)
Strong in vitro synergy between the fusion inhibitor T-20 and the CXCR4 blocker AMD-3100
CL Tremblay et al.
JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES (2000)
Sensitivity of human immunodeficiency virus type 1 to the fusion inhibitor T-20 is modulated by coreceptor specificity defined by the V3 loop of gp120
CA Derdeyn et al.
JOURNAL OF VIROLOGY (2000)
Share Paper
